Kazia Therapeutics To Request FDA Type C Meeting To Discuss Overall Survival Data In GBM And Potential NDA Filing In Alignment With FDA Initiative Project Frontrunner

Kazia Therapeutics Ltd KZIA:

• KAZIA THERAPEUTICS TO REQUEST FDA TYPE C MEETING TO DISCUSS OVERALL SURVIVAL DATA IN GBM AND POTENTIAL NDA FILING IN ALIGNMENT WITH FDA INITIATIVE PROJECT FRONTRUNNER

• KAZIA THERAPEUTICS LTD - SEEKS FDA FEEDBACK ON REGULATORY PATHWAY UNDER PROJECT FRONTRUNNER FOR PAXALISIB